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Recent studies have suggested a role for the Epstein–Barr virus-encoded RNA EBER-1 in malignant transformation.
EBER-1 inhibits the activity of the protein kinase PKR, an inhibitor of protein synthesis with tumour suppressor properties. In
human 293 cells and murine embryonic fibroblasts, transient expression of EBER-1 promoted total protein synthesis and
enhanced the expression of cotransfected reporter genes. However reporter gene expression was stimulated equally well
in cells from control and PKR knockout mice. NIH 3T3 cells stably expressing EBER-1 exhibited a greatly increased frequency
of colony formation in soft agar, and protein synthesis in these cells was relatively resistant to inhibition by the calcium
ionophore A23187. Nevertheless clones containing a high concentration of EBER-1 were not invariably tumourigenic. We
conclude that EBER-1 can enhance protein synthesis by a PKR-independent mechanism and that, although this RNA may
contribute to the oncogenic potential of Epstein–Barr virus, its expression is not always sufficient for malignant transfor-
mation. © 2002 Elsevier Science (USA)INTRODUCTION
Epstein–Barr virus (EBV) is a large DNA virus of the
herpes family that is of widespread occurrence in the
human population (Vousden and Farrell, 1994). The virus
is strongly associated with several human malignancies,
including endemic Burkitt’s lymphoma, nasopharyngeal
carcinoma, Hodgkin’s disease, and B cell lymphomas in
immunocompromised patients (Khan and Coates, 1994).
There is also evidence for the presence of EBV in a
significant proportion of cases of T cell leukaemia/lym-
phoma and other types of human tumours (Tokunaga et
al., 1993a,b; Bashir et al., 1994; Anagnostopoulos et al.,
1995; Lee et al., 1995). Although the role of the virus in the
aetiology of these diseases is not clear, EBV is an ex-
tremely potent mitogenic virus for human B lymphocytes
(Rogers et al., 1992; Sugden, 1994; Hollyoake et al., 1995)
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development of the transformed phenotype.
Resting human B lymphocytes that are infected with
EBV in vitro undergo a number of changes that are
similar to those that occur when these cells are activated
by antigens or mitogens. A significant fraction of the cells
becomes immortalized and such cells can give rise to
continuously proliferating lymphoblastoid cell lines in
culture (Sugden, 1994). The majority of these cells do not
spontaneously support productive viral replication but
remain latently infected. A restricted range of viral genes
is expressed in such cells, encoding up to six nuclear
antigens (EBNAs 1–6), three membrane proteins (LMP-1,
-2A, and -2B), and two small RNA species (EBER-1 and
EBER-2) (Rogers et al., 1992; Sugden, 1994; Rosa et al.,
1981; Jat and Arrand, 1982). The pattern of EBV gene
expression in EBV-positive tumours, as well as in a
proportion of infected B cells in vivo, can be even more
restricted (Rowe et al., 1987; MacMahon and Ambinder,
1994; Chen et al., 1995).
Although much has been learned of the functions of
the gene products expressed during viral latency, one of
the most puzzling questions concerns the roles of the
EBERs (Clemens, 1994; Arrand, 2000). These abundantly
expressed small RNAs, which are uncapped, nonpolya-
denylated, and untranslated (Lerner et al., 1981a), haveKey Words: EBER-1 RNA; Epstein–Barr virus; fibroblasts
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been identified in both nucleus (Howe and Steitz, 1986;
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Rymo, 1982; Schwemmle et al., 1992) and are frequently
used in in situ hybridisation studies to establish the EBV
status of tumours (Wu et al., 1991; Khan et al., 1992; Wu
and Kuo, 1993; Brousset et al., 1993; Randhawa et al.,
1994). However their function in the aetiology of virus
infection or cell immortalisation has remained elusive.
Early in vivo studies suggested that the EBERs are able
to stimulate DNA and protein synthesis when transiently
expressed in normal B lymphocytes (Zeuthen, 1983a,b),
and our laboratory described some preliminary evidence
suggesting that the EBERs may contribute to the estab-
lishment or maintenance of a transformed phenotype in
NIH 3T3 cells (Laing et al., 1995). Although most EBV-
immortalized cell lines and virus-positive tumours ex-
press the EBERs, there are a few exceptions (Yao et al.,
2000; Sugawara et al., 1999), suggesting that the pres-
ence of the small RNAs is not essential to the tumouri-
genic state. Moreover, while several recent reports have
provided evidence that expression of the EBERs in EBV-
negative B cell lines is oncogenic (Komano et al., 1999;
Ruf et al., 2000; Yamamoto et al., 2000), recombinant EBV
from which the EBER genes have been deleted is still
competent both to infect B cells and to give rise to
immortalized lymphoblastoid cell lines in vitro (Swami-
nathan et al., 1991). The conclusion that the EBERs are
not essential for immortalisation is perhaps not surpris-
ing in view of the fact that EBV possesses a number of
other genes with immortalising or transforming ability
(Wensing and Farrell, 2000) but it does not preclude a
role for the EBERs in contributing to the oncogenic phe-
notype of EBV-positive cells.
The EBERs are known to associate with a number of
host cell proteins, including the La antigen (lupus anti-
gen) (Hendrick et al., 1981; Lerner et al., 1981a,b), ribo-
somal protein L22 (Toczyski and Steitz, 1991), and the
interferon-inducible, double-stranded RNA (dsRNA)-de-
pendent protein kinase PKR (Clarke et al., 1991; Sharp et
al., 1993). The La antigen plays a role in the synthesis
and/or processing of RNA polymerase III transcripts
(Rinke and Steitz, 1982; Reddy et al., 1983; Mathews and
Francoeur, 1984; Stefano, 1984; Gottlieb and Steitz,
1989a,b; Maraia, 1996; Fan et al., 1997; Van Horn et al.,
1997) and in the regulation of the initiation of protein
synthesis (Xiao et al., 1994; Svitkin et al., 1994a,b; Meero-
vitch et al., 1993; Belsham et al., 1995; James et al., 1999;
Holcik and Korneluk, 2000; Wood et al., 2001) but it is not
known whether association with the EBERs modulates
these functions. In the case of L22, the binding of EBER-1
leads to the relocalisation of the ribosomal protein from
the nucleolus, where ribosomes are assembled, to the
nucleoplasm (Toczyski et al., 1994), but again the func-
tional significance of this is unresolved. The most intrigu-
ing property of the EBERs, which may be of significance
for their effects on cellular phenotype, is their ability to
bind to PKR. In virus-infected cells this protein kinase is
activated by low concentrations of dsRNA and it plays an
important role in the antiviral effects of the interferons by
inhibiting protein synthesis (Hovanessian, 1989; Meurs
et al., 1990; Mathews and Shenk, 1991). EBER-1 binds to
PKR in competition with dsRNA and, at relatively high
concentrations, is able to block the activation of the
enzyme. PKR inhibits translation as a result of its ability
to phosphorylate the  subunit of eukaryotic polypeptide
chain initiation factor 2 (eIF2). Thus, in vitro EBER-1 is
able to prevent the inhibition of protein synthesis caused
by dsRNA in the reticulocyte lysate system, which con-
tains endogenous PKR (Clarke et al., 1990a,b, 1991;
Sharp et al., 1993).
PKR is also important in the control of protein synthe-
sis and other growth-related functions in uninfected
cells. It can be activated by cellular stress conditions
such as high cell density (Petryshyn et al., 1988), growth
factor deprivation (Ito et al., 1994), and mobilisation of
calcium by the ionophore A23187 (Prostko et al., 1995;
Srivastava et al., 1995; Alca´zar et al., 1995) and it is also
implicated in the control of apoptosis (Srivastava et al.,
1998; Gil and Esteban, 2000) (reviewed in Clemens and
Elia, 1997). The wild-type form of this protein kinase
inhibits cell proliferation, whereas dominant negative
forms transform NIH 3T3 cells to a tumourigenic pheno-
type (Koromilas et al., 1992; Meurs et al., 1993; Barber et
al., 1995). Other studies have shown that additional in-
hibitors of PKR activity such as the protein p58 and the
cellular TAR binding protein also transform 3T3 cells
when overexpressed (Barber et al., 1994; Benkirane et
al., 1997). At least part of the oncogenic effect of PKR
inhibition may be due to enhanced survival of cells in the
face of physiological stresses since cells from PKR
knockout mice are resistant to apoptosis (Der et al.,
1997).
In view of the association of EBER-1 with PKR and
other proteins that may be involved in the regulation of
protein synthesis and/or cell growth, we have investi-
gated the effects of transient and stable expression of
EBER-1 in uninfected cells, in the absence of other EBV
gene products. In transient transfection experiments we
have measured the effect of coexpression of EBER-1 on
overall translation and on the synthesis of a reporter
gene product. Previous studies have shown that trans-
fection of plasmids such as those based on pBR322 has
marked effects on cellular protein synthetic activity and it
has been suggested that this results at least partially
from the activation of PKR by dsRNA produced by com-
plementary transcription from natural and cryptic pro-
moters (Svensson and Akusjarvi, 1985; Akusjarvi et al.,
1987; Kaufman and Murtha, 1987; Mori et al., 1996; Ter-
enzi et al., 1999). This results in poor translation of
plasmid-derived mRNAs. Expression of the small adeno-
virus RNA VA-1 by cotransfection is able to prevent the
activation of PKR, perhaps in a localised manner, and
this leads to the stimulation of translation of mRNAs
encoded by the plasmids. In view of this we have com-
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pared the abilities of EBER-1 and VA-1 to enhance re-
porter gene activity and have investigated the require-
ment for PKR for the effect of EBER-1.
Using stably transfected cells, we have also assayed
individual clones for their sensitivity to inhibition of pro-
tein synthesis by physiological stresses such as those
induced by the calcium ionophore A23187 or serum de-
privation. We have also determined whether there is any
change in cellular growth phenotype associated with
EBER-1 expression. Our data suggest that EBER-1 does
regulate protein synthesis in vivo but that this occurs by
a mechanism that is independent of PKR activity. More-
over, although the small viral RNA can confer some
transformed properties on NIH 3T3 cells, its expression
in the absence of other viral gene products does not
appear to be sufficient to confer an oncogenic phenotype
on these cells.
RESULTS
Transient expression of EBER-1 in 293 cells
stimulates total cellular protein synthesis
We have shown that EBER-1 is able to prevent the
inhibition of protein synthesis caused by dsRNA in the
reticulocyte lysate system in vitro (Clarke et al., 1990a,b,
1991; Sharp et al., 1993). To test whether this small RNA
is also able to enhance translation in intact cells, we
initially carried out transient transfections in 293 cells.
Following transfection with pBRLEX or its parental vector,
pBR322, RNA was prepared from cells at various time
points and a Northern blot was probed for EBER-1. To
normalize the loading, the level of the endogenous small
cellular RNA Y3 (Pruijn et al., 1993) was also determined.
In cells transfected with pBRLEX the amount of EBER-1
increased relative to the amount of Y3 RNA, reaching a
maximum at ca. 37 h posttransfection and decreasing
slowly thereafter (Fig. 1A). The effect on total cellular
protein synthesis of transfection with pBRLEX or pBR322
or with no exogenous DNA (mock transfection) was in-
vestigated by pulse labelling the cells with [35S]methi-
onine at various times posttransfection (Fig. 1B). The rate
of incorporation of methionine following mock transfec-
tion increased with time as the cell mass increased. In
contrast, in cells transfected with pBR322 there was little
or no increase, up to 36 h. However, when the EBER-1
gene was expressed, this inhibition was reversed, such
that the pBRLEX-transfected cells showed very similar
rates of protein synthesis to the mock-transfected con-
trols. The relative rates of methionine incorporation in the
three cell populations were reflected in the changes in
total protein content of the cultures over this time period
(data not shown), suggesting that they are an indication
of alterations in cell growth. These results indicate that
transfection of pBR322 causes an inhibition of overall
protein synthesis and cell growth and that this inhibition
is relieved by the expression of the EBER-1 gene present
in the otherwise identical plasmid.
Effects of EBER-1 on reporter gene expression
We have also investigated the effect of transient
EBER-1 expression in 293 cells on enzyme activity en-
coded by a cotransfected reporter gene. Further, we
compared the ability of this RNA with that of adenovirus
VA-1 RNA to regulate reporter gene expression in rela-
tion to overall protein accumulation (as a measure of cell
growth) over the posttransfection period. Cells were co-
transfected with plasmids pMHVA, pJJJ-I, or pBR322 to-
gether with one of the two reporter constructs, pRSV-
LacZ-II or pJatLac, both of which carry the lacZ gene.
Forty hours after transfection, total protein content was
FIG. 1. Transient expression of EBER-1 in transfected cells and effect
on total protein synthesis. A: 293 cells were transfected with 0.5 g/cm2
of either pBR322 or the EBER-1-encoding plasmid pBRLEX. At the
indicated times the cells were harvested and cytoplasmic RNA was
extracted. The RNA was separated on a 7 M urea, 10% polyacrylamide
gel and probed for EBER-1 and the endogenous cellular RNA Y3. For
comparison total cytoplasmic RNA was also extracted from the EBV-
positive human Burkitt’s lymphoma cell line Daudi and analysed in
parallel (right-hand lane). An autoradiogram of the hybridized Northern
blot is shown. B: 293 cells were transfected with pBR322 or pBRLEX, or
with no DNA (mock-transfected). At the indicated times after transfec-
tion cells were incubated in the presence of [35S]methionine for 1 h and
harvested. Acid precipitable counts were measured by scintillation
counting. The error bars indicate standard deviations.
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measured by Bradford assay and equal amounts of pro-
tein were used for the measurement of -galactosidase
activity (Table 1). The -galactosidase-specific activity
was stimulated about sixfold in cells cotransfected with
VA-1, relative to cells cotransfected with pBR322, regard-
less of which promoter was controlling the expression of
the reporter gene. VA-1 expression had little effect on
overall protein accumulation in the transfected cells. In
contrast cotransfection of the EBER-1-encoding plasmid
pJJJ-1 had much less effect on the activity of the enzyme
(per microgram of total protein). However the total -ga-
lactosidase activity was enhanced by a factor of 3 to
fivefold, largely as a result of the increase in total protein
content. These results in Table 1 indicate that VA-1 has a
specific effect on the expression of a cotransfected re-
porter gene, while EBER-1 does not, but that EBER-1 is
more stimulatory for cell growth and overall protein syn-
thesis (including synthesis of the reporter enzyme). The
latter effect, obtained in this experiment with a different
EBER-1 expression plasmid, is consistent with the re-
sults in Fig. 1, suggesting that the EBER-1 effect on
protein synthesis and accumulation is not peculiar to a
particular expression vector or individual plasmid prep-
aration.
Is PKR required for the effect of EBER-1 on reporter
gene expression?
Although EBER-1 interacts with PKR to block its acti-
vation in vitro (Sharp et al., 1993), the viral RNA also binds
to other cellular proteins, including the La antigen and
ribosomal protein L22 (Glickman et al., 1988; Lerner et
al., 1981a; Toczyski and Steitz, 1993; Toczyski et al., 1994).
We therefore investigated the requirement for PKR in the
effects of EBER-1 on the expression of a cotransfected
reporter gene by comparing the ability of cell lines from
PKR-positive and -negative mice to respond to the trans-
fection of plasmid pLEX-III. We also measured reporter
gene expression in the two cell lines following exposure
of the cells to the PKR inhibitor 2-aminopurine (2-AP). In
this experiment the reporter gene was chloramphenicol
acetyltransferase (CAT), encoded by the plasmid
pCMV19CAT. At 48 h posttransfection cell extracts were
prepared and CAT activity was assayed by the acetyla-
tion of [14C]chloramphenicol, with separation of the
mono- and diacetylated products by thin layer chroma-
tography (Gorman et al., 1982; Crabb et al., 1989). Figure
2 shows that expression of EBER-1 in the control murine
embryonic fibroblasts enhanced CAT activity by seven-
fold. This effect was identical in the cells from PKR/
mice, thus indicating that PKR is not required for the
stimulation. In contrast, 2-AP only weakly stimulated CAT
expression in the PKR/ cells (by 1.7-fold) and had no
effect on the knockout cells.
Establishment of stably transfected EBER-positive
and EBER-negative cell lines
To obtain stable cell lines that express EBER-1, to-
gether with the corresponding controls, NIH 3T3 cells
were cotransfected with two plasmids using the strategy
outlined under Materials and Methods. All cells received
plasmid pCMV19hyg containing a hygromycin resistance
gene driven by the cytomegalovirus immediate early pro-
moter, which allowed the subsequent selection of suc-
cessfully transfected cells in the presence of 200 g/ml
hygromycin. The second plasmid was either pLEXZII,
containing the lacZ and EBER-1 genes, or pRSVLacZII,
which lacked all EBV sequences but was otherwise
identical.
Several independent EBER-positive and EBER-nega-
tive clones were isolated that had successfully incorpo-
rated the two transfected plasmids. When assayed for
-galactosidase expression from the lacZ gene using the
TABLE 1
Comparison of the Effects of EBER-1 and VA-1 on Cellular Protein Content and Expression of a Cotransfected Reporter Gene
pJatLac
Transfected plasmids
pRSVLacZII pJJJ-1 pMHVA-1 pBR322
Total cell protein per well
(g)
-Galactosidase activity
Total units Units/g protein
  6.8 1.0 18.5 2.0 2.72 0.30
  21.8 3.4* 53.8 5.0** 2.47 0.23
  9.2 1.7 153.5 9.9** 16.68 1.08**
  9.5 0.8 7.1 0.6 0.75 0.06
  23.3 1.7** 38.7 2.8** 1.66 0.12**
  9.0 1.9 39.5 3.5** 4.39 0.39**
Note. 293 cells were transfected with 0.1 g/cm2 of the indicated -galactosidase reporter plasmid and 0.4 g/cm2 of the EBER-1 expression
plasmid pJJJ-I, the VA-1 expression plasmid pMHVA-1 or the control plasmid pBR322. Forty hours after transfection the cells were lysed by
freeze–thawing, total protein content was measured, and -galactosidase activity was determined. The data are means  standard errors of six
determinations. One unit of -galactosidase activity corresponds to 1 nmol of ONPG hydrolysed.
* Significantly different from the pBR322 control (P  0.005).
** Significantly different from the pBR322 control (P  0.0001).
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chromogenic substrate X-Gal, all cells in the selected
hygromycin-resistant clones showed positive staining,
although the conversion of X-Gal appeared to be some-
what heterogeneous within each clonal population (Fig.
3). The expression of -galactosidase was used as a
marker for the incorporation of the EBER-1 gene in the
cells transfected with pLEXZII since the latter gene lies
within 0.25 kb of lacZ in this plasmid. Analysis by North-
ern blotting of the clones established using this protocol
confirmed that all of the -galactosidase-positive clones
cotransfected with pCMV19hyg and pLEXZII also ex-
pressed EBER-1 (Fig. 4A). However the level of expres-
sion of the small RNA was quite variable between
clones, with a maximum which was approximately equiv-
alent to the level of the endogenous small cytoplasmic
RNA Y3. This compares with a ratio of EBER-1 to Y3
expression of about 4.5 for the EBV-positive Burkitt’s
lymphoma cell line, Daudi (Fig. 4B). The variability of
EBER-1 expression may reflect differences in gene copy
number or in the site of integration in the transfected
FIG. 2. The protein kinase PKR is not required for effects of EBER-1 on expression of a cotransfected reporter gene. Embryonic fibroblasts from
PKR/ and PKR/mice were transfected with the CAT reporter plasmid pCMV19CAT (0.5 g) and either pcDNA-II (control plasmid) or the EBER-1
expression plasmid pLEX-III (0.5 g). Where indicated, the PKR inhibitor 2-AP (10 mM) was added to the cells 24 h later. The cells were harvested
after 48 h and equal amounts of highly diluted extracts (equivalent to 2 g total protein per 150 l assay) were assayed for CAT activity by acetylation
of [14C]chloramphenicol, followed by TLC separation of the products (Crabb et al., 1989; Gilligan et al., 1990) (A). The origin of the samples is indicated
(Ori) and the positions of unmodified chloramphenicol (C) and its 1-acetylated (1-AC), 3-acetylated (3-AC), and 1,3-diacetylated (1,3-(AC)2) derivatives
are indicated. The % conversions of substrate to products were measured by phosphorimaging and the data are plotted in B.
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cells. As expected, none of the cells cotransfected with
pCMV19hyg and pLacZII contained any RNA that hybrid-
ized with the EBER-1 probe.
Morphology and growth characteristics of EBER-
positive and EBER-negative 3T3 cells
The morphologies of the EBER-positive and EBER-
negative clones could be readily compared both by stain-
ing of the monolayers with Giemsa and by an in situ
assay for -galactosidase using X-Gal (MacGregor and
Caskey, 1989). Both assays showed that, although all the
clones continued to grow as monolayers, the EBER-
positive clones acquired a markedly more spindle-
shaped morphology (Fig. 3). This change in cell morphol-
ogy suggested the possibility that the cells had acquired
a more transformed phenotype (Cox and Der, 1994) and
so the growth characteristics of the various clones were
determined. However, the results, summarized in Table
2, indicate that neither the growth rates nor the overall
cell densities at the end of the exponential phase of
growth were significantly different between the EBER-
positive and the EBER-negative 3T3 cells.
The ability of cells that normally grow only in mono-
layer to form colonies in soft agar is a more sensitive
assay for cell transformation than measurement of over-
all growth rates per se. We therefore determined the
FIG. 3. Cell morphology and expression of -galactosidase in EBER-positive and EBER-negative cell clones. NIH 3T3 cells that had been
transfected with plasmid pCMV19hyg and either pRSVLacZII or pLEXZII (both containing the lacZ gene) were selected by resistance to hygromycin.
Individual clones were maintained in exponential growth in monolayer culture for 4 days and then stained with Giemsa (A and B). To monitor the
expression of -galactosidase (C and D), cells were washed with PBS, fixed in 2% formaldehyde/0.2% glutaraldehyde in PBS, and then assayed for
in situ enzyme activity (MacGregor and Caskey, 1989). A: Giemsa-stained clone A2121 (EBER-negative) cells; B: Giemsa-stained clone C32
(EBER-positive) cells; C: in situ -galactosidase activity in clone A2121 cells; D: in situ -galactosidase activity in clone C34 (EBER-positive) cells. Note
the more spindle-shaped morphology of the EBER-positive cells in comparison with the control cells in each case.
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ability of individual cell clones to grow in this anchorage-
independent fashion. A marked difference was observed
in the behaviour of the cells in this assay; none of the
EBER-negative clones showed any significant ability to
produce colonies in soft agar and behaved similar to
typical 3T3 cells in this regard, whereas all the EBER-
positive clones tested exhibited efficient colony forma-
tion. Approximately 15–19% of the EBER-1-positive cells
seeded produced colonies in soft agar after 4–6 weeks
(Fig. 5).
Regulation of protein synthesis in EBER-positive and
EBER-negative 3T3 cells
To determine whether the expression of EBER-1 in 3T3
cells was associated with changes in protein synthesis,
we analysed the overall translational activity of the cells
under optimal growth conditions and in response to the
physiological stresses induced either by treatment with
the calcium ionophore A23187 or by serum deprivation.
Under optimal conditions little difference could be ob-
FIG. 4. EBER-1 expression in clones of stably transfected 3T3 cells. A: total cytoplasmic RNA was extracted from the indicated cell clones and from
the EBV-positive human Burkitt’s lymphoma cell line Daudi. The RNA was subjected to electrophoresis on a denaturing polyacrylamide gel and
hybridised with probes for EBER-1 and the endogenous small cellular RNA Y3. Both probes had the same specific radioactivity. Lanes 1–2: clones
transfected with the control plasmid pRSVLacZII (clones A42 and A2121, respectively); lanes 3–5: clones transfected with the EBER-1 expression
plasmid pLEXZII (clones B135, C32, and B26, respectively); lane 6: Daudi cells. The bands corresponding to EBER-1 and the mouse or human Y3 RNA
are indicated. B: the extent of hybridisation was quantified by cutting out the relevant bands and counting the radioactivity in a liquid scintillation
counter. The data are expressed as the calculated ratios of EBER-1 to Y3 RNA levels.
259EPSTEIN–BARR VIRUS SMALL RNA AND CELL GROWTH REGULATION
served in the rates of total protein synthesis between
EBER-negative and -positive cells, although the highest
EBER-expressing cells showed somewhat less incorpo-
ration than the other clones (Table 3A). These results are
largely consistent with the lack of any major difference
between EBER-positive and EBER-negative cells in their
doubling times during exponential growth (Table 2).
In contrast, in the presence of A23187 consistent dif-
ferences in the extent of inhibition of protein synthesis
were apparent (Table 3(B)). In clones A2121 and A42
(EBER-negative) the incorporation of [35S]methionine was
more sensitive to inhibition by low doses of the iono-
phore than in clone C32 (high level EBER-1 expressing).
This was particularly noticeable in the presence of 0.1
M A23187, when incorporation was inhibited by 18.4
and 19.8% in the two EBER-negative clones but was only
inhibited by 3.5% in clone C32. Independent assays em-
ploying another high EBER-1 expressing clone (D33)
confirmed the reduced sensitivity of protein synthesis to
low concentrations of the ionophore (data not shown).
TABLE 2
Growth Characteristics of EBER-Positive and EBER-Negative
NIH 3T3 Cell Clones
Clone EBER-1 statusa
Doubling time
(h)
Saturation density
(105/cm2)
A2121  20 3.9
A42  20 3.9
F35  19 4.4
B61  23 2.5
B13  18 2.0
B26  23 1.8
B135  23 2.8
C32  20 3.9
C34  17 5.3
Note. Cell clones were grown in monolayer culture in 16 mm dishes
for up to 15 days and cell numbers were determined at regular inter-
vals. All clones reached confluency after 7–8 days.
a , EBER-1 negative; , low EBER-1 expression; , high EBER-1
expression (see Fig. 4).
FIG. 5. Ability of EBER-positive vs EBER-negative cells to form colo-
nies in soft agar. NIH 3T3 cells that had been transfected with plasmid
pCMV19hyg and either pRSVLacZII or pLEXZII were selected as de-
scribed under Materials and Methods and individual clones were
seeded in soft agar at a density of 1  104 cells per 10 cm2. The
cultures were examined for colony formation after 4–6 weeks. Data are
shown for four EBER-positive clones (B13, B135, C32, C34) and three
EBER-negative clones (A2121, A42, F35).
TABLE 3
Rates of Protein Synthesis and Sensitivity to Inhibition by A23187
or Serum Deprivation in EBER-Positive and EBER-Negative Cell
Clones
(A) Clone EBER-1 statusa
Rate of protein synthesis
(cpm  103) (SD)
A2121  7.95 1.97
A42  9.68 1.66
B26  7.57 1.23
B135  7.39 4.23
C32  5.41 1.27
(B) Clone EBER-1 statusa
% Inhibition of protein synthesis
in presence of A23187
0.1 M 0.25 M 0.5 M 1 M
A2121  18.4 38.7 66.1 83.9
A42  19.8 42.9 67.4 85.3
B26  8.9 40.3 73.6 87.8
B135  10.3 37.4 68.3 85.9
C32  3.5 17.4 44.6 76.9
(C) Clone EBER-1 statusa
% Inhibition of protein synthesis
in presence of low serum (% v/v)
5% 1% 0.5% 0.1%
A2121  26.1 49.8 48.9 56.1
A42  14.1 46.7 51.5 54.8
F35  28.3 55.6 56.1 59.6
B26  17.1 43.4 44.1 59.4
B135  24.3 56.4 63.9 70.1
C32  19.4 55.3 61.8 56.4
Note. (A) Clones of EBER-negative cells and EBER-positive cells
were labelled with [35S]methionine for 1 h as described under Materials
and Methods and incorporation of radioactivity into acid-insoluble
material was determined on equal numbers of cells. (B) Cell clones
were pretreated for 15 min with the indicated concentrations of A23187
and pulse-labelled with [35S]methionine for 1 h. The data are means
from three independent experiments, each performed in quadruplicate.
(C) Cell clones were incubated in the presence of various concentra-
tions of serum (between 0.1 and 10% (v/v)) for 22 h and then pulse-
labelled with [35S]methionine in the same medium for 2 h. Cells were
washed in PBS and harvested as described under Materials and
Methods. Total protein content and methionine incorporation were
determined and the data are expressed as the % inhibition of radioac-
tivity incorporated per g protein, relative to the value obtained in the
presence of 10% serum.
a , EBER-1 negative; , low EBER-1 expression; , high EBER-1
expression (see Fig. 4).
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Clones B26 and B135 (low level EBER-1-expressing) ex-
hibited an intermediate sensitivity to 0.1 M A23187 but
were inhibited as much as the EBER-negative controls at
higher concentrations (Table 3(B)).
When the various clones were subjected to serum
deprivation for 22 h, protein synthesis declined substan-
tially, reflecting the loss of essential growth factors
needed to maintain optimal levels of translation (Scor-
sone et al., 1987; Kleijn et al., 1998). However there were
no consistent differences in response between clones
expressing EBER-1 at various levels and clones that did
not contain the small RNA (Table 3(C)). Thus the mech-
anism(s) by which EBER-1 acts to protect cells against
the effects of A23187 are not sufficient to prevent the
inhibitory effects of the loss of serum growth factors on
protein synthesis.
Tumourigenesis assays
Although colony formation in soft agar is an indication
of a loss of normal growth control in response to EBER-1
expression, these results alone do not establish whether
the small RNA is able to cause fully malignant transfor-
mation of mouse 3T3 cells, as has been observed in the
case of human B cell lines (Komano et al., 1999; Ruf et al.,
2000; Yamamoto et al., 2000). We therefore determined
the ability of several EBER-positive and EBER-negative
3T3 cell clones to form tumours in nude mice. As nega-
tive and positive controls, two other 3T3 cell lines ex-
pressing wild-type and mutant forms of PKR (Meurs et
al., 1992), respectively, were also assayed for tumour
formation. Up to 40 days after injection the majority of
mice which received EBER-negative clones failed to pro-
duce tumours of any significant size (Table 4), although
tumours did appear at late times in some animals in-
jected with these cells. Such “spontaneous” tumour for-
mation is often seen with 3T3 cells (Rubin and Xu, 1989;
Chow et al., 1994). Of the EBER-positive clones exam-
ined, one expressing a high level of the small RNA (clone
C32) was highly malignant and formed rapidly growing
tumours with a high frequency (Table 4). However an-
other clone (D33) in which EBER expression was equally
high (data not shown), as well as clones in which the
level of the small RNA was five- to sevenfold less, were
not tumourigenic at up to 40 days and the only tumours
which appeared showed much longer lag periods. In-
deed these clones had a lower frequency of tumourigen-
esis than the control cells (Table 4). As previously re-
ported (Meurs et al., 1993), cells expressing a mutant
form of PKR (K296R) (clone 12.3) were rapidly tumouri-
genic, whereas cells expressing wild-type PKR (clone
68.11) were not.
These data suggest that whereas expression of
EBER-1 may contribute to transformation of NIH 3T3
cells, as determined by growth in soft agar, it does not
necessarily result in a malignant phenotype such as that
seen when mutant PKR is expressed in these cells.
Nevertheless, where tumours did arise in mice injected
with the EBER-positive C32 cell line, they were always
found to contain high levels of the RNA. Moreover, two
late-arising tumours obtained from mice injected with
clones B135 and B26, respectively (cell lines which orig-
inally contained only a low level of EBER-1), were found
to express a higher amount of the RNA than previously,
comparable to that in clone C32 (data not shown). It is
possible that these tumours may have arisen from sub-
populations of cells which had a higher level of EBER
expression due to an increased rate of transcription,
increased stability of the transcript, or amplification of
the transfected EBER gene. These cells might have had
a selective growth advantage in vivo. RNA from the
spleen of a mouse carrying a C32 tumour was negative
for EBER-1 by Northern blotting.
DISCUSSION
Effects of transient transfection of EBER-1 on protein
synthesis in vivo
Our data show that EBER-1 has the ability to counter-
act the inhibition of cellular protein synthesis and re-
porter gene expression which is brought about by tran-
sient transfections with pBR322 or its derivatives, regard-
less of whether the EBER-1 gene is present in cis (Fig. 1)
or in trans (Table 1) relative to the inhibitory sequences.
Kaufman and co-workers have shown that the transla-
tional efficiency of mRNA expressed from transfected
plasmids containing identical transcription units can vary
depending on the vector backbone. PBR322-based vec-
TABLE 4
Tumour Growth in Nude Mice Injected with EBER-Positive and
EBER-Negative 3T3 Cells and 3T3 Cells Expressing Wild-Type or
Mutant PKR
Clone EBER-1 status Tumour fraction
Lag time
(days)
A2121  3/10 22, 39, 39
A42  1/5 39
B26  0/5
B135  0/5
C32  4/5 21, 23, 30, 30
D33  0/5
Clone PKR status Tumour fraction
Lag time
(days)
12.3 K296R mutant 2/2 15, 17
68.11 Wild-type 0/3
Note. Nude mice were injected subcutaneously with 1  106 cells
per animal as described under Materials and Methods and monitored
for appearance of tumours on a daily basis. The data indicate the
fraction of mice which developed tumours at times up to 40 days and
the lag times to the appearance of these tumours.
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tors in particular yield mRNAs that are poorly translated
due to the activation of the dsRNA-dependent eIF2
kinase PKR (Kaufman et al., 1989). The origin of the
dsRNA that activates PKR under these conditions is not
clear, but since bacteriophage promoters have been
reported to support cellular RNA polymerase II activity
(Sandig et al., 1993), it is possible that transcription from
cryptic promoters within the plasmid accounts for the
effect. Translation of plasmid-encoded mRNAs can be
stimulated by treatment of cells with the PKR inhibitor
2-aminopurine or by expression of dominant negative
PKR, VA-1 RNA, or a nonphosphorylatable form of the
PKR substrate eIF2 (Kaufman et al., 1989; Mori et al.,
1996; Terenzi et al., 1999). However stimulation of total
cellular protein synthesis in the transfected cell popula-
tions was not observed in these studies (Kaufman and
Murtha, 1987; Kaufman et al., 1989; Terenzi et al., 1999). It
is possible that transfection may lead to activation of PKR
and the phosphorylation of eIF2 in a localised manner,
thus affecting the translation only of plasmid-derived
sequences. This is consistent with the stimulation by
VA-1 of expression of the cotransfected lacZ and other
reporter genes (Table 1) (Akusjarvi et al., 1987; Kaufman
and Murtha (1987)) but a lack of effect on overall protein
synthesis or protein content (Table 1). It is also possible
that the plasmid-derived RNA is present in a pool sepa-
rate from the cellular RNAs and that plasmid-derived
dsRNA leads to activation of PKR and inhibition of trans-
lation only in that pool. The strong association of PKR
with ribosomes and the rough endoplasmic reticulum
(Galabru and Hovanessian, 1987; Dubois and Hovanes-
sian, 1990; Jeffrey et al., 1995; Zhu et al., 1997; Raine et
al., 1998) may facilitate such functional compartmental-
isation. It is to be noted, however, that generalized ef-
fects of transiently transfected plasmids on overall pro-
tein synthesis in a culture could only be expected when
the efficiencies of transfection are very high, such as in
the case of 293 cells.
In contrast to VA-1, EBER-1 causes no specific stimu-
lation of expression of a cotransfected reporter gene
(Table 1), but it is able to prevent the general inhibition of
protein synthesis and reporter gene expression following
transfection of 293 cells (Table 1; Fig. 1). The differential
effects of VA-1 and EBER-1 in transfected cells are in
contrast to the results of in vitro studies, where the two
viral RNAs have both been shown to bind and inhibit PKR
(Clarke et al., 1990b, 1991; Sharp et al., 1993). EBER-1 can
also to some extent complement the function of VA-1 in
adenovirus deletion mutants (Bhat and Thimmappaya,
1983, 1985), so the two RNAs are likely to have at least
overlapping regulatory effects. However, reporter gene
expression is equally responsive to EBER-1 in cells that
do not express PKR (Fig. 2). Thus, although we cannot
rule out the possibility that PKR is regulated by EBER-1 in
vivo, the predominant effect on reporter gene expression
is clearly not dependent on the protein kinase. Interest-
ingly, a large stimulatory effect of VA RNAs on reporter
gene expression in PKR/ cells has also been noted
but was attributed in this case to an mRNA stabilisation
effect (Terenzi et al., 1999).
It remains to be established whether the association
of EBER-1 with either the La antigen (Lerner et al., 1981a)
or the ribosomal protein L22 (Toczyski and Steitz, 1991;
Toczyski et al., 1994) is relevant to the observed effect on
protein synthesis. The La antigen has been shown to
have a variety of actions, including roles in the initiation
of translation of mRNAs containing internal initiation
sites or 5 oligopyrimidine tracts (Svitkin et al., 1994a,b;
Meerovitch et al., 1993; Belsham et al., 1995; Holcik and
Korneluk, 2000; Wood et al., 2001) and in the regulation of
PKR (through its ability to bind and unwind dsRNA)
(Bachmann et al., 1990; Xiao et al., 1994; Hu¨hn et al.,
1997; James et al., 1999). It is therefore possible that the
association between EBER-1 and La might be of signif-
icance for the observed effect of the viral RNA on protein
synthesis in transfected cells. However the majority of
the La antigen is located in the cell nucleus and its role
in general translational control remains uncertain. A
translational regulatory function has also recently been
suggested for L22 (Wood et al., 2001) but L22 that is not
associated with ribosomes also has a predominantly
nuclear location in EBV-infected cells and EBER-1 does
not appear to bind to L22 on mature cytoplasmic ribo-
somes (Toczyski et al., 1994).
Effects of stable expression of EBER-1 on protein
synthesis and cellular phenotype
Unlike its effects on general protein synthesis in tran-
siently transfected cells, EBER-1 does not stimulate
translation in stable cell lines under normal growth con-
ditions (Table 3). This is consistent with the similar ex-
ponential growth rates of EBER-positive and -negative
cell clones. However under certain cellular stress con-
ditions it is possible that the RNA blocks the activation of
PKR and thus enhances protein synthesis. For example,
the protective effect of EBER-1 expression on inhibition
of protein synthesis by A23187 in 3T3 cells suggests an
in vivo effect on PKR activation. Low concentrations of
the Ca2 ionophore have been shown to activate the
protein kinase (Prostko et al., 1995; Srivastava et al.,
1995), and in cells in which PKR activation is prevented
by expression of dominant negative mutants or other
inhibitory proteins, protein synthesis is less sensitive to
inhibition by A23187 (Srivastava et al., 1995). Expression
of a nonphosphorylatable form of eIF2 (the major in vivo
substrate of PKR) has a similar protective effect (Srivas-
tava et al., 1995). However other eIF2 kinase(s) can also
regulate translation in response to perturbations of intra-
cellular Ca2 (Kimball et al., 2001). In contrast to the
situation with the ionophore, protein synthesis was not
inhibited differentially by serum deprivation in EBER-
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positive vs EBER-negative clones. Thus the effects of
EBER expression on overall translation may only be
manifested under specific conditions of physiological
stress, for which A23187 treatment is a model. Our stud-
ies have not addressed the issue of whether the synthe-
sis of specific proteins may be enhanced selectively by
EBER expression. A recent report (Kitagawa et al., 2000)
shows that interleukin-10 is induced by the EBERs in
EBV-negative Akata cell clones but this appears to be
mediated by an increase in the level of mRNA for the
cytokine.
The ability of all the EBER-positive clones tested to
grow in soft agar indicates that these cells have acquired
a new phenotype, which is independent of the expres-
sion of any other EBV gene products. Although colony
formation in soft agar is suggestive of growth transfor-
mation (Cox and Der, 1994), the lack of a consistent effect
of EBER-1, even when expressed at relatively high levels,
on tumourigenesis suggests that the small RNA alone is
not always sufficient to cause a fully malignant pheno-
type, at least in 3T3 cells. This would not be surprising in
view of the multifactorial nature of oncogenesis and it
would be of interest to determine (e.g., by stable cotrans-
fection approaches) what additional cellular events, such
as elevated expression of cellular oncogenes or other
EBV genes, can complement the effects of EBER-1 ex-
pression to produce malignant phenotypes. Recent stud-
ies of the in vivo effects of EBER expression in EBV-
negative Akata and BJAB cells have demonstrated fully
malignant transformation (Komano et al., 1999; Ruf et al.,
2000; Yamamoto et al., 2000); however, these results
were obtained using cell lines derived from Burkitt’s
lymphomas which already contain other oncogenic mu-
tations (Farrell et al., 1991; Komano et al., 1998).
In view of the effects of EBER-1 on PKR activity (Clarke
et al., 1990b; Sharp et al., 1993) inactivation of this protein
kinase is a strong candidate for the mechanism by which
the growth phenotype is modified in stable EBER-ex-
pressing cell lines. PKR has been implicated in the con-
trol of cell growth and apoptosis in numerous studies
(Proud et al., 1991; Koromilas et al., 1992; Barber et al.,
1994; Gil and Esteban, 2000; Srivastava et al., 1998)
(reviewed in Clemens and Elia, 1997). Interestingly, the
most tumourigenic clone (C32), which had a high level of
EBER-1, also contained a higher amount of PKR than
normal, as determined by immunoblotting (A. Elia and
M. J. Clemens, unpublished data). In this clone elevated
expression of PKR was clearly no longer incompatible
with cell growth (Clemens and Elia, 1997), suggesting
that the PKR was inactive. Such a phenomenon has been
seen in other systems where the protein kinase is inac-
tive (Thomis and Samuel, 1992). Nevertheless, since we
have not yet examined the effects of stable expression of
EBER-1 in cells which are PKR-negative, we cannot ex-
clude the possibility that the activity of the La antigen,
ribosomal protein L22, and/or other pathways are also
regulated by the viral RNA in a way that contributes to the
phenotypic changes we observe in mouse 3T3 cells. If
PKR is the target, then clearly the effects of EBER-1 on
growth can be distinguished from those on reporter gene
expression since the protein kinase is dispensable for
the latter (Fig. 2). The EBER-induced synthesis of inter-
leukin-10, which may be partially responsible for the
enhanced growth and oncogenicity of EBV-negative
Akata cells, has also been reported to be independent of
PKR regulation (Kitagawa et al., 2000).
It is possible that EBER-1 is not as effective as domi-
nant negative PKR (Table 4) or other PKR inhibitors in
inducing malignancy in 3T3 cells (Koromilas et al., 1992;
Meurs et al., 1993; Barber et al., 1994, 1995; Benkirane et
al., 1997) because the levels of EBER-1 obtained in our
clones were too low. Our earlier in vitro studies have
indicated that high concentrations of EBER-1 (ca. 10
g/ml and above) are necessary to inhibit PKR activity
(Clarke et al., 1990b; Sharp et al., 1993), as is the case for
a number of other small virally encoded RNAs (Gunnery
et al., 1990; Mathews and Shenk, 1991; Clemens et al.,
1994). If this is true in vivo then only cells that accumulate
EBER-1 to a high level would be expected to be tumouri-
genic. Consistent with this, we have observed that oc-
casional tumours that arose from clones that were orig-
inally low EBER expressors had acquired higher levels of
the RNA, perhaps reflecting the growth advantage that is
conferred on cells that are unable to activate their en-
dogenous PKR. The maximum concentration of EBER-1
in the 3T3 cell clones, estimated by comparison with the
level of the endogenous Y3 RNA (Hendrick et al., 1981), is
approximately 105 molecules per cell (Fig. 4). Using the
reported value for intracellular water volume of 3T3 cells
of 1.45 l per 106 cells (Sussman and O’Brien, 1985), this
corresponds to an RNA concentration of about 7 g/ml.
This level of EBER-1 is substantially less than that found
in EBV-infected tumour cells (Lerner et al., 1981a;
Randhawa et al., 1994), although it is likely to be suffi-
cient to prevent, at least partially, the activation of PKR by
dsRNA. The consistent loss of growth inhibition in soft
agar of cell clones with low EBER-1 levels may indicate
that partial inhibition of PKR affects some pathways more
than others or that EBER-1 acts by more than one mech-
anism with some processes being regulated by much
lower concentrations of the RNA.
Is there a role for the EBERs in infection and/or cell
transformation by EBV?
Since both EBER-1 and EBER-2 are usually expressed
to high levels during latent EBV infection, it is reasonable
to assume that they have a function in the effects of the
virus as a mitogenic and immortalising agent. Neverthe-
less, the significance of these RNA species is still enig-
matic. It seems unlikely that the EBERs are required
during the early phase of infection of resting B cells since
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significant expression of these RNAs does not occur
until after 36 h (in contrast to the earlier expression of
other viral gene products associated with latent infection
(Rooney et al., 1989; Alfieri et al., 1991)). Furthermore the
small RNAs are not essential to the virus, at least under
some circumstances, since cases are known of EBV-
positive cells that do not contain the EBERs (Mitterer et
al., 1995; Sugawara et al., 1999; Yao et al., 2000). EBV
mutants in which the EBER genes have been deleted are
still able to infect and immortalize B cells and such
EBER-negative viruses can also replicate (Swaminathan
et al., 1991, 1992).
Of the three proteins with which the EBERs associate,
PKR has the clearest role in the regulation of viral repli-
cation since it is an important mediator of some of the
antiviral effects of the interferons (Meurs et al., 1992).
However both the La antigen and the ribosomal protein
L22 have recently been implicated in the regulation of
translation of hepatitis C and other viruses (Xiao et al.,
1994; Svitkin et al., 1994a,b; Meerovitch et al., 1993;
Belsham et al., 1995; James et al., 1999; Holcik and
Korneluk, 2000; Wood et al., 2001) and an additional role
for these proteins during EBV infection cannot be ex-
cluded. It is possible that the EBERs are involved in
counteracting an interferon-induced inhibition of EBV
functions by blocking the activation of PKR that may
otherwise occur in response to the expression of RNAs
with extensive secondary structure (Sharp et al., 1993;
Elia et al., 1996a,b). Consistent with this, BJAB cells
transfected with the EBER genes show down-regulation
of PKR activity (Yamamoto et al., 2000). The fact that
Swaminathan et al. (1992) were unable to observe any
difference in the interferon sensitivity of EBER-positive
and EBER-negative virus during infection of B cells in
culture does not necessarily rule out a role for the EBERs
in the regulation of PKR in vivo since the interferons exert
their antiviral effects by multiple mechanisms (Hovanes-
sian, 1991). It has not been established whether PKR
activity is necessary for a protective effect of interferon
treatment against infection of B cells by EBV in vitro.
However, in the intact organism inhibition of PKR may
contribute to the evasion by EBV of interferon-mediated
antiviral effects, as is the case for several other viruses
(Gale and Katze, 1998), and could aid the early establish-
ment of a latent infection.
In the present work we have addressed only the po-
tential role of EBER-1 as a regulatory molecule and it is
possible that EBER-2 plays an additional and distinct role
in EBV-infected cells. Although EBER-2 can also bind to
PKR (and competes with EBER-1 for the same site on the
protein (Sharp et al., 1993)), it is often present at much
lower concentrations in vivo and is unlikely to fulfill an
identical and redundant function. A precedent for this is
seen in the case of the VA-1 and VA-2 RNAs of adenovi-
rus, where VA-2 has additional properties not involving
PKR (Liao et al., 1998). Further work will be required to
address the possibility of distinct roles for the two ubiq-
uitously expressed small RNAs in the physiology of EBV
infection.
MATERIALS AND METHODS
Plasmids for transfection
The EBER-1 expression plasmid pBRLEX, containing
the EBER-1 gene (167 bp) and upstream promoter ele-
ments required for optimal transcription (Howe and Shu,
1989), was constructed by subcloning the EcoRI–HindIII
fragment from plasmid pJJJ-I (Jat and Arrand, 1982) into
pBR322. The plasmid pLEX-III, containing the EBER-1
gene and the same upstream elements, was constructed
by subcloning the relevant EcoRI–BamHI fragment from
pJJJ-1 into the polylinker region of plasmid pcDNA-II
(Invitrogen). The VA-1 expression plasmid pMHVA-1
(Mellits and Mathews, 1988), containing nucleotides
10,579–10,810 from adenovirus 2 in a pBR322 backbone,
was a gift from Dr. K. H. Mellits. The plasmids pJatLac
(Masson et al., 1992) and pRSVLacZII (a gift from Dr. W.
Ankenbauer) are reporter plasmids containing the lacZ
gene from Escherichia coli, under the control of the rat
-actin promoter or the long terminal repeat of the Rous
sarcoma virus (RSV-LTR), respectively. The CAT reporter
plasmid pCMV19CAT was derived from the promoterless
plasmid pKSSV0CAT (Tsonis et al., 1988) by cloning the
CMV promoter upstream of the CAT coding region. The
plasmid pLEXZII was constructed by cloning 510 bp of
DNA from the EBV genome, encompassing nucleotides
6286–6796 of the B95–8 viral sequence (Baer et al., 1984)
into pRSVLacZII at a unique BamHI site. Thus plasmids
pRSVLacZII and pLEXZII are identical except for the
presence in the latter of an insert comprising the EBER-1
gene and 342 bp of upstream sequence containing re-
gions important for efficient transcription of EBER-1. All
plasmids were purified by caesium chloride gradient
centrifugation.
Transient transfections
Human 293 cells were grown in DMEM (Gibco-BRL)
containing 10% heat-inactivated foetal calf serum (FCS)
and were maintained in a subconfluent state by regular
passaging. At least 6 h before transfection cells were
seeded at 2.5  104 cells/cm2 into 6- or 24-well plates.
Transfections were carried out by the calcium phosphate
precipitation method (Graham and van der Eb, 1973). For
measurement of reporter gene expression the cells were
harvested 40 h later. Transfection efficiencies, as deter-
mined by staining the cells with X-Gal (MacGregor and
Caskey, 1989), were greater than 90% for 293 cells.
Embryonic fibroblasts from control and PKR knockout
mice (Yang et al., 1995) were grown in DMEM, supple-
mented with 1 mM 2-mercaptoethanol and 10% (v/v) FCS.
The cells were transfected as described above and har-
vested after 48 h for assay of reporter gene expression.
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Stable transfection and selection of cell clones
NIH 3T3 cells were seeded at 1  104 cells per cm2
and transfected after 24 h with 0.05 g per cm2 of the
hygromycin-resistance selection plasmid pCMV19hyg
and 0.2 g per cm2 of either pLacZII or pLEXZII, using
(N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium
methyl sulfate) (DOTAP; BCL) as recommended by the
supplier. After 48 h selection of stable transfectants was
carried out in the presence of 200 g/ml hygromycin B
(BCL) and resistant clones were isolated. Those clones
expressing -galactosidase, as determined by in situ
staining with X-Gal (MacGregor and Caskey, 1989), were
then subjected to further subcloning by repeated rounds
of limiting dilution.
RNA extraction and Northern blotting
RNA was extracted from cultured cells by lysis in 10
mM Tris–HCl pH 8.6, 140 mM NaCl, 1.5 mM MgCl2, 0.5%
NP-40, 1 mM DTT, 20 mM vanadyl-ribonucleoside com-
plex (Sambrook et al., 1989). Nuclei were removed by
centrifugation at 12,000 g for 5 min at 4°C. An equal
volume of proteinase K digestion buffer (200 mM Tris–
HCl pH 8.0, 25 mM EDTA pH 8.0, 300 mM sodium chlo-
ride, 2% SDS, and 100 g/ml proteinase K) was added to
the supernatant and the reaction mix was incubated at
37°C for 30 min. The RNA was extracted with phenol/
chloroform and precipitated with ethanol. The RNA was
denatured by heating to 65°C for 5 min in 2 vol form-
amide sample buffer (99% formamide, 10 mM Tris–HCl
pH 8.0, 0.1% bromphenol blue, 0.1% xylene cyanol FF) and
resolved by electrophoresis in 10% polyacrylamide/7 M
urea gels. It was transferred to Hybond-N membranes
(Amersham) in 25 mM sodium phosphate buffer (pH 6.5)
and UV-crosslinked to the membranes. Blots were pre-
hybridized in 6 SSC (0.9 M NaCl, 90 mM trisodium
citrate), 5 Denhardt’s solution (0.5% Ficoll, 0.5% bovine
serum albumin, 0.5% polyvinyl pyrrolidone), 0.5% SDS,
and 100 g/ml of denatured salmon sperm DNA at 68°C
for 1–2 h. Hybridisation was then carried out overnight
using radiolabelled antisense transcripts to EBER-1 or
the small cellular RNA hY3 (Pruijn et al., 1993). These
were transcribed using T7 RNA polymerase in the pres-
ence of [32P]UTP from plasmids pAVAinv (K. Laing, un-
published data) and pTZ19Y3 (a gift from Dr W. Van
Venrooij, Nijmegen), linearised with Sau3A and EcoRI,
respectively. After hybridisation the blots were washed
sequentially for 15 min at 68°C in 2 SSC, 1 SSC, and
0.1 SSC containing 0.1% SDS and then subjected to
autoradiography.
Measurements of protein content and protein
synthesis
Cells were washed in phosphate-buffered saline (PBS)
and the total protein content was determined by the
Bradford assay. Rates of overall protein synthesis were
measured by labelling the cells with [35S]methionine
(5–10 Ci/ml) in complete medium for 1 h at 37°C.
Subsequently the cells were harvested and washed in
PBS. They were then pelleted and resuspended in ice-
cold 5% w/v trichloroacetic acid plus 0.5% w/v sodium
pyrophosphate at 4°C for 30 min. The precipitates were
filtered through GF/C filters (Whatman). Alternatively,
cells were lysed in situ in 0.3 M NaOH; the lysates were
incubated at 37°C for 1 h and spotted onto Whatman 3
MM filter discs and the protein was precipitated with 10%
trichloroacetic acid. In both cases the filters were
washed with cold 5% w/v trichloroacetic acid and cold
ethanol and the radioactivity determined by scintillation
counting. For studies on the effects of the Ca2 iono-
phore A23187 cells were preincubated for 15 min with
various concentrations of A23187 (in a final concentra-
tion of 0.6% (v/v) dimethylsulphoxide (DMSO)) before
addition of labelled methionine and further incubation as
above. Control cultures received the same amount of
DMSO alone.
Measurement of -galactosidase and
chloramphenicol acetyltransferase activity
-galactosidase activity was measured in lysates of
transfected cells by the conversion of o-nitrophenol--D-
galactoside (ONPG) into galactose and the chro-
mophoreo-nitrophenol. The latter was detected by its
absorbance at 420 nm as described by MacGregor et al.
(1991). In situ expression of -galactosidase in trans-
fected cells was determined by staining the fixed cells
with X-Gal (MacGregor and Caskey, 1989). CAT activity
was determined as described by Gorman et al. (1982),
using [14C]chloramphenicol as substrate. High dilutions
of the cell extracts were used as the source of CAT
activity to ensure that the enzyme activity was limiting in
the assays. The various acetylated forms of chloram-
phenicol were separated by thin-layer chromatography
on silica gel-coated plates, using chloroform:methanol
(95:5 v/v) as solvent, and the distribution of radioactivity
in the products was determined by phosphorimaging.
Determination of cell growth rates and colony
formation
NIH 3T3 cells were grown in DMEM medium contain-
ing 10% FCS and were maintained in a subconfluent
state by regular passaging. The kinetics of cell growth
were determined by measuring cell numbers after
trypsinisation and counting in a Coulter counter (Coulter
Electronics). For assays of colony formation in soft agar,
stably transfected cells were suspended in 1 ml of 0.3%
soft agar/1 DMEM/20% FCS and overlaid on 0.5% low
melting point agar containing the same components at a
density of 1  104 cells per 10 cm2. The cultures were
then supplemented with 1  DMEM/20% FCS with 200
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g/ml hygromycin B. After incubation for 4–6 weeks the
percentage cloning efficiency was calculated as the
number of visible colonies divided by the number of cells
plated  100.
Tumourigenesis assays
NIH 3T3 cells were grown to 70% confluency,
trypsinized, and resuspended in PBS at 1  107 cells/ml.
Four- to six-week-old nude mice (CD1/CD1) were in-
jected subcutaneously on the upper left flank with 1 
106 cells. All procedures were carried out under mild
general anaesthesia and in accordance with the appro-
priate U.K. guidelines. The animals were examined on a
routine basis and tumours were measured with calipers
every 2–3 days. The time required to produce tumours of
a mean diameter of 5 mm was determined as the latency
period.
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